ALDEI Deinove S.A.

DEINOVE expands its range of cosmetic active ingredients

DEINOVE expands its range of cosmetic active ingredients

DEINOVE expands its range of cosmetic active ingredients

  • Its second innovative carotenoid has the particularity of absorbing blue light, which is responsible for premature skin ageing, the appearance of skin spots, a loss of radiance and vitality.
  • Efficacy tests carried out on human skin explants confirmed its protective properties and also revealed that it plays an active role on key parameters contributing to skin lightening.
  • The new ingredient will be officially launched at in-Cosmetics Global (31 March-2 April, Barcelona).

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-based active ingredients for cosmetics, confirms being in the process of finalizing the development of its 2nd proprietary cosmetic active ingredient, for its official launch at the upcoming in-Cosmetics Global trade show.

DEINOVE has developed a new cosmetic active ingredient, produced by fermentation and based on a totally original carotenoid, designed to restore radiance and vitality to the skin.

Its ability to absorb blue light1 and its outstanding antioxidant properties had been demonstrated in vitro.

Ex vivo studies have since been carried out, confirming these properties and revealing additional features, particularly in terms of complexion homogeneity and brightness, which are particularly sought by the cosmetics industry.

The active is currently being clinically tested and data will be available for the official launch.

"We are actively preparing the launch of this 2nd proprietary active ingredient which will be officially presented at in-Cosmetics Global, the world's largest trade show dedicated to cosmetic ingredients, taking place in Barcelona from March 31 to April 2. After a promising preview at in-Cosmetics Asia last fall, we will be able to present robust data demonstrating the efficacy and original mechanism of action of this active ingredient, " says Coralie MARTIN, Marketing Manager at DEINOVE.



ABOUT DEINOVE

DEINOVE is a French biotechnology company, a leader in disruptive innovation, which aims to help meet the challenges of antibiotic resistance and the transition to a sustainable production model for the cosmetics and nutrition industries.

DEINOVE has developed a unique and comprehensive expertise in the field of rare bacteria that it can decipher, culture, and optimize to disclose unsuspected possibilities and induce them to produce biobased molecules with activities of interest on an industrial scale. To do so, DEINOVE has been building and documenting since its creation an unparalleled biodiversity bank that it exploits thanks to a unique technological platform in Europe.

DEINOVE is organized around two areas of expertise:

  • ANTIBIOTICS, New-generation anti-infective drugs: A first antibiotic candidate, DNV3837, is now in Phase II. The Company is also pursuing the systematic exploration of biodiversity to supply its portfolio with new leads, drawing notably on partnerships with bioMérieux and Naicons (AGIR program supported by Bpifrance).
  • BIOACTIVES, Active ingredients of natural origin with cosmetics as the first market: DEINOVE is already marketing a first cosmetic active ingredient, a second in partnership with Greentech and plans to launch new assets in 2020. Several other cosmetic actives are in development, including with Oléos (Hallstar Group) and Dow. It also runs a program in animal nutrition with Groupe Avril.

Within the Euromedecine science park located in Montpellier, DEINOVE employs 60 employees, mainly researchers, engineers, and technicians, and has filed more than 350 patent applications internationally. The Company has been listed on EURONEXT GROWTH® since April 2010.

CONTACTS

Investors

Coralie Martin

Communication, Marketing and Investor Relations

Ph.: +33 (0)4 48 19 01 60



Media

ALIZE RP

Caroline Carmagnol

Ph.: +33 (0)6 64 18 99 59



 






1 Blue light is emitted not only by the sun, but also by screens (TV, computers, smartphones, tablets), electronics and lighting. This light radiation is known for its harmful effects on the health and beauty of the skin. Digital pollution is an emerging issue in cosmetics, given the increasing exposure to blue light produced by screens or LEDs.



Attachment

EN
19/02/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Deinove S.A.

 PRESS RELEASE

Conversion of the receivership proceedings into judicial liquidation p...

Conversion of the receivership proceedings into judicial liquidation proceedings CONVERSION OF THE RECEIVERSHIP PROCEEDINGS INTO JUDICIAL LIQUIDATION PROCEEDINGS DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent, global challenge of antibiotic resistance, announces that on January 23, 2023, the Montpellier Commercial Court rendered a judgment converting the receivership proceedings, initiated on November 7, 2022, into a judicial liquidation proceedings (“procédure de liquidation jud...

 PRESS RELEASE

Conversion de la procédure de redressement judiciaire en liquidation j...

Conversion de la procédure de redressement judiciaire en liquidation judiciaire CONVERSION DE LA PROCEDURE DE REDRESSEMENT JUDICIAIRE EN LIQUIDATION JUDICIAIRE DEINOVE (Euronext Growth Paris : ALDEI), société de biotechnologie française pionnière dans l’exploration et l'exploitation de la biodiversité bactérienne pour relever le défi urgent et planétaire de la résistance aux antimicrobiens, annonce que le Tribunal de Commerce de Montpellier a rendu le 23 janvier 2023 un jugement actant la conversion de la procédure de redressement judiciaire, initiée le 7 novembre 2022, en liquidation jud...

 PRESS RELEASE

DEINOVE - Update on the receivership proceedings

DEINOVE - Update on the receivership proceedings DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent, global challenge of antibiotic resistance, announces that, in the context of the receivership proceedings (“procédure de redressement judiciaire”) opened on November 7, 2022, the Montpellier Commercial Court met on January 13, 2023 to examine the case and reserved its decision until January 23, 2023. The listing of the Company's shares (ISIN: FR0010879056), which has been suspended sin...

 PRESS RELEASE

DEINOVE - Point sur la procédure de redressement judiciaire

DEINOVE - Point sur la procédure de redressement judiciaire DEINOVE (Euronext Growth Paris : ALDEI), société de biotechnologie française pionnière dans l’exploration et l'exploitation de la biodiversité bactérienne pour relever le défi urgent et planétaire de la résistance aux antimicrobiens, annonce que, dans le cadre de la procédure de redressement judiciaire ouverte le 7 novembre 2022, le Tribunal de Commerce de Montpellier s'est réuni le 13 janvier 2023 afin d'examiner l’affaire et a mis sa décision en délibéré au 23 janvier 2023. La cotation des actions de la Société (ISIN : FR0010879...

 PRESS RELEASE

DEINOVE - Update on the Receivership Proceedings

DEINOVE - Update on the Receivership Proceedings DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent, global challenge of antibiotic resistance, announces that, in the context of the receivership proceedings (“procédure de redressement judiciaire”) opened on November 7, 2022, the Montpellier Commercial Court has met on December 16, 2022, and postponed the examination of the case to January 13, 2023. The continuation of the observation period (“période d'observation”) was requested by th...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch